MiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma

Doxorubicin (DOX) is one of the most frequently used anti-cancer drugs and the front line option for hepatocellular carcinoma (HCC) treatment. However, the clinical applications of DOX are restricted largely due to its toxicity and chemoresistance. Here, we report that miR-375 and DOX were co-delive...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Yin-Ping, Liao, Jia-Zhi, Lu, Ya-Qi, Tian, De-An, Ye, Feng, Zhao, Peng-Xuan, Xiang, Guang-Ya, Tang, Wang-Xian, He, Xing-Xing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415965/
https://www.ncbi.nlm.nih.gov/pubmed/28624193
http://dx.doi.org/10.1016/j.omtn.2017.03.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415965/
https://www.ncbi.nlm.nih.gov/pubmed/28624193
http://dx.doi.org/10.1016/j.omtn.2017.03.010

Ejemplares similares